Bicara Therapeutics Inc. (BCAX) AI Stock Analysis

• Market Cap: $690.27M
• Dividend Yield: N/A
• Average Volume (3M): 556.65K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 54,523,327
• 10 Day Avg. Volume: 497,770
• 30 Day Avg. Volume: 556,655
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $40.00
• Price Target Upside: 215.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Bicara Therapeutics' overall score reflects the high-risk nature associated with early-stage biotechnology companies, characterized by a lack of revenue and heavy reliance on external financing. While the company's strong cash position offers some financial flexibility, the technical analysis points to a neutral to slightly bearish market sentiment. Valuation remains challenging due to the absence of earnings, adding to the stock's risk profile.

Positive Factors

Clinical Trial Progress

Ficerafusp alfa addresses the key resistance mechanism associated with EGFR resistance.

Financial Health

BCAX ended 4Q with cash/equivalents of $489.7M, expected to fund operations into 1H29.

Market Valuation

BCAX shares are significantly undervalued based on ficerafusp alfa’s broad potential in EGFR+ solid tumors and strong balance sheet that should support development until approval.

Negative Factors

Enrollment Challenges

Enrollment in the Ph1/1b study is currently on hold due to possible changes in the standard of care in an earlier line of therapy.

Financial Performance

The company's GAAP net loss was wider than expected, driven by higher-than-expected operating expenses.

Safety Concerns

46.4% of patients treated with the combo experienced a G3+ TRAE, with G3 ALT/AST elevations occurring in 14% and 7% of patients, respectively; 7.1% of patients discontinued treatment due to a TRAE.

Bicara Therapeutics Inc. Business Overview & Revenue Model

Company Description

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

How the Company Makes Money

Bicara Therapeutics Inc. generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of its drug candidates once they receive regulatory approval. Additionally, Bicara might engage in collaborations for research and development to fund its projects. These partnerships can provide upfront payments, milestone payments, and royalties on future sales, thereby contributing to the company's earnings.

Bicara Therapeutics Inc. Financial Statement Overview

Summary

Bicara Therapeutics is in a high-risk phase typical for early-stage biotechnology firms, with no revenue and significant reliance on external funding. The strong cash position offers some financial flexibility, but ongoing losses and negative cash flow from operations highlight significant financial challenges. Investors should be cautious and aware of the potential for volatility as the company focuses on R&D activities.

Income Statement

Bicara Therapeutics Inc. has reported no revenue in the past three years, leading to negative EBIT and net income. The company is heavily reliant on external funding, as evidenced by its substantial negative net income and EBIT. The lack of revenue growth is a significant concern and reflects the high-risk nature of biotechnology companies in the research and development phase.

Balance Sheet

The company has a robust cash position with significant cash and short-term investments relative to its total debt, resulting in a negative net debt. However, the equity position has improved from a negative standpoint to a positive one, indicating a better capital structure. There is minimal debt, which mitigates financial risk, but the company still shows signs of instability due to fluctuating equity values.

Cash Flow

Bicara Therapeutics has negative operating and free cash flow, highlighting its reliance on financing activities to fund operations. The lack of revenue generation and continuous negative cash flow from operations is a concern. However, successful financing rounds have bolstered cash reserves, reflecting investor confidence despite operational challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
-69.44M	-82.39M	-39.89M	-37.66M
	EBITDA
-81.47M	-82.39M	-51.96M	-37.72M
	Net Income Common Stockholders
-59.48M	-68.00M	-51.98M	-37.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.16M	489.71M	230.44M	4.16M
	Total Assets
0.00	510.00M	233.98M	6.70M
	Total Debt
0.00	738.00K	657.00K	0.00
	Net Debt
0.00	-488.97M	-229.78M	-4.16M
	Total Liabilities
17.28M	18.12M	382.75M	105.51M
	Stockholders Equity
-17.28M	491.88M	-148.77M	-98.80M
Cash Flow		Free Cash Flow
-53.22M	-74.82M	-46.21M	-32.27M
	Operating Cash Flow
-52.76M	-74.75M	-45.63M	-32.08M
	Investing Cash Flow
-405.00K	-9.00K	-586.00K	-192.00K
	Financing Cash Flow
529.71M	334.03M	272.50M	31.70M

Bicara Therapeutics Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$682.21M	―	-37.72%	―	―	-3.08%
ABUS	52 Neutral	$668.27M	―	-68.76%	―	-65.98%	14.00%
LENZ	51 Neutral	$708.13M	―	-25.68%	―	―	68.93%
DNTH	50 Neutral	$540.67M	―	-32.60%	―	351.48%	80.10%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
BCAX	41 Neutral	$690.27M	―	34.94%	―	―	―
COGT	35 Underperform	$681.96M	―	-99.54%	―	―	-2.53%